{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:03:10Z","timestamp":1768010590000,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2375-8","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T18:57:40Z","timestamp":1514487460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Jang-Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Woo","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungha","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tea-Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-7606","authenticated-orcid":false,"given":"Dong-Ryeol","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Jun","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"2375_CR1","volume-title":"World health statistics 2010","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. World health statistics 2010. Geneva: World Health Organization; 2010."},{"key":"2375_CR2","volume-title":"National Diabetes Fact Sheet, 2011","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheet11.htm. Accessed 26 Oct 2011."},{"issue":"7","key":"2375_CR3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","volume":"291","author":"CS Fox","year":"2004","unstructured":"Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844\u201350.","journal-title":"JAMA"},{"key":"2375_CR4","doi-asserted-by":"crossref","unstructured":"Morbidity & Mortality. Am J Kidney Dis. 2010;55(1, Supplement 1):S83\u201394.","DOI":"10.1053\/j.ajkd.2009.10.019"},{"issue":"5","key":"2375_CR5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1744-9987.2012.01088.x","volume":"16","author":"H Hirakata","year":"2012","unstructured":"Hirakata H, Nitta K, Inaba M, Shoji T, Fujii H, Kobayashi S, et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial. 2012;16(5):387\u2013435.","journal-title":"Ther Apher Dial"},{"issue":"6","key":"2375_CR6","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D Zeeuw De","year":"2004","unstructured":"De Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309\u201320.","journal-title":"Kidney Int"},{"issue":"5","key":"2375_CR7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ki.1996.481","volume":"50","author":"JA Breyer","year":"1996","unstructured":"Breyer JA, Bain RP, Evans JK, Nahman NS, Lewis EJ, Cooper M, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int. 1996;50(5):1651\u20138.","journal-title":"Kidney Int"},{"issue":"10","key":"2375_CR8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123(10):754\u201362.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2375_CR9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","volume":"286","author":"HC Gerstein","year":"2001","unstructured":"Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421\u20136.","journal-title":"JAMA"},{"issue":"6","key":"2375_CR10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus a blood pressure\u2013independent effect. Circulation. 2002;106(6):672\u20138.","journal-title":"Circulation"},{"issue":"11","key":"2375_CR11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","volume":"139","author":"K Wachtell","year":"2003","unstructured":"Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139(11):901\u20136.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2375_CR12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"2375_CR13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"12","key":"2375_CR14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"H-H Parving","year":"2001","unstructured":"Parving H-H, Lehnert H, Br\u00f6chner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"2375_CR15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"key":"2375_CR16","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159\u2013219.","journal-title":"Eur Heart J."},{"issue":"1","key":"2375_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community. J Clin Hypertension. 2014;16(1):14\u201326.","journal-title":"J Clin Hypertension"},{"issue":"10","key":"2375_CR18","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1093\/ndt\/gfn230","volume":"23","author":"J Galle","year":"2008","unstructured":"Galle J, Schwedhelm E, Pinnetti S, B\u00f6ger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008;23(10):3174\u201383.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2375_CR19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","volume":"74","author":"G Bakris","year":"2008","unstructured":"Bakris G, Burgess E, Weir M, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"2375_CR20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40256-013-0004-9","volume":"13","author":"JB Park","year":"2013","unstructured":"Park JB, Sung K-C, Kang S-M, Cho EJ. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb Study). Am J Cardiovasc Drugs. 2013;13(1):47\u201356.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"2375_CR21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","volume":"3","author":"G Eknoyan","year":"2013","unstructured":"Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):5\u201314.","journal-title":"Kidney Int"},{"issue":"4","key":"2375_CR22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2375_CR23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/009286150003400202","volume":"34","author":"A Phillips","year":"2000","unstructured":"Phillips A, Ebbutt A, France L, Morgan D. The international conference on harmonization guideline \u201cstatistical principles for clinical trials\u201d: issues in applying the guideline in practice. Drug Inform J. 2000;34(2):337\u201348.","journal-title":"Drug Inform J"},{"issue":"4","key":"2375_CR24","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bmcl.2011.12.116","volume":"22","author":"TW Kim","year":"2012","unstructured":"Kim TW, Yoo BW, Lee JK, Kim JH, Lee K-T, Chi YH, et al. Synthesis and antihypertensive activity of pyrimidin-4 (3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT 1) antagonists. Bioorg Med Chem Lett. 2012;22(4):1649\u201354.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"2375_CR25","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3390\/molecules20033868","volume":"20","author":"TF Kellici","year":"2015","unstructured":"Kellici TF, Tzakos AG, Mavromoustakos T. Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors. Molecules. 2015;20(3):3868\u201397.","journal-title":"Molecules"},{"issue":"6","key":"2375_CR26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/FJC.0b013e31821795d0","volume":"57","author":"S Yi","year":"2011","unstructured":"Yi S, Kim T-E, Yoon SH, Cho J-Y, Shin S-G, Jang I-J, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57(6):682\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"13","key":"2375_CR27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","volume":"330","author":"S Klahr","year":"1994","unstructured":"Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330(13):877\u201384.","journal-title":"N Engl J Med"},{"issue":"19","key":"2375_CR28","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421\u201331.","journal-title":"JAMA"},{"key":"2375_CR29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","volume":"363","author":"L Appel","year":"2010","unstructured":"Appel L, Wright Jr J, Greene T, Agodoa L, Astor B, Bakris G, et al. The long-term effects of a lower blood pressure goal on progression of hypertensive chronic kidney disease in African-Americans. New Engl J Med. 2010;363:918\u201329.","journal-title":"New Engl J Med."},{"issue":"362","key":"2375_CR30","first-page":"1575","volume":"2010","author":"AS Group","year":"2010","unstructured":"Group AS. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;2010(362):1575\u201385.","journal-title":"N Engl J Med"},{"issue":"373","key":"2375_CR31","first-page":"2103","volume":"2015","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;2015(373):2103\u201316.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2375-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T18:58:40Z","timestamp":1514487520000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2375-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2375-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"632"}}